Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: Synthesis of new transporter inhibitors as tools for this study

British Journal of Pharmacology

Volumn 141, Issue 3, 2004, Pages 457-467

  Ruiz Llorente, Lidia ^a   Ortega Gutiérrez, Silvia ^b   Viso, Alma ^b   Sánchez, María G ^a   Sánchez, Ana M ^a   Fernández, Carlos ^c   Ramos, José A ^b   Hillard, Cecilia ^d   Lasunción, Miguel A ^a,c   López Rodríguez, María L ^b   Díaz Laviada, Inés ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Anandamide degradation; Anandamide uptake inhibitors; Endogenous cannabinoid system; Fatty acid amidohydrolase; Prostate PC 3 cells

Indexed keywords

AMIDE; ANANDAMIDE; ANANDAMIDE UPTAKE INHIBITOR; CANNABINOID RECEPTOR ANTAGONIST; FATTY ACID AMIDASE; N (3 FURYLMETHYL)ARACHIDONAMIDE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N (FUR 3 YLMETHYL)HEXADEC 9 ENAMIDE; N (FUR 3 YLMETHYL)OCTADEC 9 ENAMIDE; N (FUR 3 YLMETHYL)OCTADECA 9,12 DIENAMIDE; N (FUR 3 YLMETHYL)OCTADECA 9,12,15 TRIENAMIDE; N [(1 METHYL 2 THIEN 3 YL)ETHYL]ICOSA 5,8,11,14 TETRAENAMIDE; PHLORETIN; RECEPTOR BLOCKING AGENT; UCM 119; UNCLASSIFIED DRUG; VANILLOID RECEPTOR; VANILLOID RECEPTOR ANTAGONIST; VERAPAMIL;

ACTIVE TRANSPORT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MALE; MICHAELIS CONSTANT; PRIORITY JOURNAL; PROSTATE; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TEMPERATURE DEPENDENCE; WESTERN BLOTTING;

AMIDOHYDROLASES; ARACHIDONIC ACIDS; BIOTRANSFORMATION; CALCIUM CHANNEL BLOCKERS; CANNABINOIDS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EPITHELIAL CELLS; FURANS; HUMANS; MALE; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; POLYUNSATURATED ALKAMIDES; PROSTATE;

EID: 10744227377     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705628     Document Type: Article

References (52)

1. AHLUWALIA, B.S., RAJGURU, S.U. & NOLAN, G.H. (1985). The effect of Δ9-tetrahydrocannabinol in utero exposure on rat offspring fertility and ventral prostate gland morphology. J. Androl., 6, 385-391.
2. AMERI, A. (1999). The effects of cannabinoids on the brain. Prog. Neurobiol., 58, 315-348.
3. BELTRAMO, M., STELLA, N., CALIGNANO, A., LIN, S.Y., MAKRIYANNIS, A. & PIOMELLI, D. (1997). Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science, 277, 1094-1097.
4. BISOGNO, T., MAURELLI, S., MELCK, D., DE PETROCELLIS, L. & DI MARZO, V. (1997). Biosynthesis, uptake and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem., 272, 3315-3323.
5. CRAVATT, B.F. & LICHTMAN, A.H. (2003). Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr. Opin. Chem. Biol., 7, 469-475.
6. DAY, T.A., RAKHSHAN, F., DEUTSCH, D.G. & BARKER, E.L. (2001). Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol. Pharmacol., 59, 1369-1375.
7. DEUTSCH, D.G., GLASER, S.T., HOWELL, J.M., KUNZ, J.S., PUFFENBARGER, R.A., HILLARD, C.J. & ABUMRAD, N. (2001). The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J. Biol. Chem., 276, 6967-6973.
8. DEUTSCH, D.G., OMEIR, R., ARREAZA, G., SALEHANI, D., PRESTWICH, G.D., HUANG, Z. & HOWLETT, A. (1997). Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem. Pharmacol., 53, 255-260.
9. DEUTSCH, D.G., UEDA, N. & YAMAMOTO, S. (2002). The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot. Essent. Fatty Acids, 66, 201-210.
10. DEVANE, W.A., HANUS, L., BREUER, A., PERTWEE, R.G., STEVENSON, L.A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
11. DÍAZ-LAVIADA, I., LARRODERA, P., DİAZ-MECO, M.T., CORNET, M.E., GUDDAL, P.H., JOHANSEN, T. & MOSCAT, J. (1990). Evidence for a role of phosphatidylcholine-hydrolysing phospholipase C in the regulation of protein kinase C by ras and src oncogenes. EMBO J., 9, 3907-3912.
12. DI MARZO, V., FONTANA, A., CADAS, H., SCHINELLI, S., SCHWARTZ, J.C. & PIOMELLI, D. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 372, 686-691.
13. DI MARZO, V., MELCK, D., BISOGNO, T. & DE PETROCELLIS, L. (1998). Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci., 21, 521-528.
14. 3H]anandamide by rabbit platelets. Eur. J. Biochem., 270, 3498-3506.
15. FOLCH, J., LEES, M. & SLOANE STANLEY, G.H. (1957). A simple method for the isolation and purification of total lipids from animal tissue. J. Biol. Chem., 226, 497-509.
16. FOWLER, C.J. & JACOBSSON, S.O. (2002). Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide-targets for drug development? Prostaglandins Leukot. Essent. Fatty Acids, 66, 193-200.
17. FOWLER, C.J., TIGER, G., LÓPEZ-RODRÍGUEZ, M.L., VISO, A., ORTEGA-GUTIÉRREZ, S. & RAMOS, J.A. (2003). Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin. J. Enzyme Inhib. Med. Chem., 18, 225-231.
18. GIANG, D.K. & CRAVATT, B.F. (1997). Molecular characterization of human and mouse fatty acid amide hydrolases. Proc. Natl. Acad. Sci. U.S.A., 94, 2238-2242.
19. GIUFFRIDA, A., BELTRAMO, M. & PIOMELLI, D. (2001). Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J. Pharmacol. Exp. Ther., 298, 7-14.
20. GLASER, S.T., ABUMRAD, N.A., FATADE, F., KACZOCHA, M., STUDHOLME, K.M. & DEUTSCH, D.G. (2003). Evidence against the presence of an anandamide transporter. Proc. Natl. Acad. Sci. U.S.A., 100, 4269-4274.
21. HARCLERODE, J. (1984). Endocrine effects of marijuana in the male: preclinical studies. NIDA Res. Monogr., 44, 46-64.
22. HILLARD, C.J., EDGEMOND, W.S., JARRAHIAN, A. & CAMPBELL, W.B. (1997). Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem., 69, 631-638.
23. HILLARD, C.J. & JARRAHIAN, A. (2000). The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem. Phys. Lipids, 108, 123-134.
24. HILLARD, C.J. & JARRAHIAN, A. (2003). Cellular accumulation of anandamide: consensus and controversy. Br. J. Pharmacol., 140, 802-808.
25. JARRAHIAN, A., MANNA, S., EDGEMOND, W.S., CAMPBELL, W.B. & HILLARD, C.J. (2000). Structure-activity relationships among N-arachidonylethanolamine (anandamide) head group analogues for the anandamide transporter. J. Neurochem., 74, 2597-2606.
26. KLEIN, T.W., NEWTON, C.A. & FRIEDMAN, H. (2001). Cannabinoids and the immune system. Pain Res. Manage., 6, 95-101.
27. LÓPEZ-RODRÍGUEZ, M.L., VISO, A., ORTEGA-GUTIÉRREZ, S., FERNÁNDEZ-RUIZ, J. & RAMOS, J.A. (2002). Endocannabinoid transporter inhibitors. Curr. Med. Chem. Central Nervous System Agents, 2, 129-141.
28. LÓPEZ-RODRÍGUEZ, M.L., VISO, A., ORTEGA-GUTIÉRREZ, S., FOWLER, C.J., TIGER, G., DE LAGO, E., FERNÁNDEZ-RUIZ, J. & RAMOS, J.A. (2003). Design, synthesis and biological evaluation of new endocannabinoid uptake process inhibitors: comparison with effects upon fatty acid amidohydrolase. J. Med. Chem., 46, 1512-1522.
29. LÓPEZ-RODRÍGUEZ, M.L., VISO, A., ORTEGA-GUTIÉRREZ, S., LASTRES-BECKER, I., GONZÁLEZ, S., FERNÁNDEZ-RUIZ, J. & RAMOS, J.A. (2001a). PCT/ES01/00305 (WO 02/12167 A1).
30. LÓPEZ-RODRÍGUEZ, M.L., VISO, A., ORTEGA-GUTIÉRREZ, S., LASTRES-BECKER, I., GONZÁLEZ, S., FERNÁNDEZ-RUIZ, J. & RAMOS, J.A. (2001b). Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. J. Med. Chem., 44, 4505-4508.
31. MACCARRONE, M., BARI, M., BATTISTA, N. & FINAZZI-AGRÒ, A. (2002). Estrogen estimulates arachidonoylethanolamide release from human endothelial cells and platelet activation. Blood, 100, 4040-4048.
32. MACCARRONE, M., BARI, M., LORENZON, T., BISOGNO, T., DI MARZO, V. & FINAZZI-AGRÒ, A. (2000a). Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J. Biol. Chem., 275, 13484-13492.
33. MACCARRONE, M., BARI, M., MENICHELLI, A., GIULIANI, E., DEL PRINCIPE, D. & FINAZZI-AGRO, A. (2001). Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. Eur. J. Biochem., 268, 819-825.
34. MACCARRONE, M., CECCONI, S., ROSSI, G., BATTISTA, N., PAUSELLI, R. & FINAZZI-AGRÒ, A. (2003). Anandamide activity and degradation are regulated by early postnatal aging and follicle-stimulating hormone in mouse sertoli cells. Endocrinology, 144, 20-28.
35. MACCARRONE, M., DE FELICI, M., BARI, M., KLINGER, F., SIRACUSA, G. & FINAZZI-AGRO, A. (2000b). Down-regulation of anandamide hydrolase in mouse uterus by sex hormones. Eur. J. Biochem., 267, 2991-2997.
36. MELCK, D., DE PETROCELLIS, L., ORLANDO, P., BISOGNO, T., LAEZZA, C., BIFULCO, M. & DI MARZO, V. (2000). Supression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology, 141, 118-126.
37. MIMEAULT, M., POMMERY, N., WATTEZ, N., BAILLY, C. & HENICHART, J. (2003). Anti-proliferative and apoptotic effects of anandamide in human prostatic cencer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate, 56, 1-12.
38. PATRICELLI, M.P. & CRAVATT, B.F. (2001). Proteins regulating the biosynthesis and inactivation of neuromodulatory fatty acid amides. Vitam. Horm., 62, 95-131.
39. PIOMELLI, D., BELTRAMO, M., GLASNAPP, S., LIN, S.Y., GOUTOPOULOS, A., XIE, X.-Q. & MAKRIYANNIS, A. (1999). Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. U.S.A., 96, 5802-5807.
40. PUROHIT, V., AHLUWAHLIA, B.S. & VIGERSKY, R.A. (1980). Marihuana inhibits dihydrotestosterone binding to the androgen receptor. Endocrinology, 107, 848-850.
41. RUIZ, L., MIGUEL, A. & DÍAZ-LAVIADA, I. (1999). 9-Tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett., 458, 400-404.
42. 1 in the human prostate gland. Prostate, 54, 95-102.
43. 2 cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal, 15, 851-859.
44. SCHUEL, H., BURKMAN, L.J., LIPPES, J., CRICKARD, K., FORESTER, E., PIOMELLI, D. & GIUFFRIDA, A. (2002). N-acylethanolamines in human reproductive fluids. Chem. Phys. Lipids, 121, 211-227.
45. 1). Br. J. Pharmacol., 129, 227-230.
46. SUGIURA, T. & WAKU, K. (2002). Cannabinoid receptors and their endogenous ligands. J. Biochem., 132, 7-12.
47. TSOU, K., NOGUERON, M.I., MUTHIAN, S., SAÑUDO-PEÑA, M.C., HILLARD, C.J., DEUTSCH, D.G. & WALKER, J.M. (1998). Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neurosci. Lett., 254, 137-140.
48. VELASCO, L., RUIZ, L., SÁNCHEZ, M.G. & DÍAZ-LAVIADA, I. (2001). 9-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Eur. J. Biochem., 268, 531-535.
49. WALEH, N.S., CRAVATT, B.F., APTE-DESHPANDE, A., TERAO, A. & KILDUFF, T.S. (2002). Transcriptional regulation of the mouse fatty acid amide hydrolase gene. Gene, 291, 203-210.
50. WENGER, T., LEDENT, C., CSERNUS, V. & GERENDAI, I. (2001). The central cannabinoid receptor inactivation suppresses endocrine reproductive functions. Biochem. Biophys. Res. Commun., 284, 363-368.
51. WENGER, T. & MOLDRICH, G. (2002). The role of endocannabinoids in the hypothalamic regulation of visceral functions. Prostaglandins Leukot. Essent. Fatty Acids, 66, 301-307.
52. WILSON, R.I. & NICOLL, R.A. (2002). Endocannabinoid signaling in the brain. Science, 296, 678-682.